Arbutus plans $230M Dutch auction tender offer at $5.00-$5.75/share

Arbutus Biopharma Corp

Tender offer to repurchase up to $230M of common shares at $5.00-$5.75/share, funded from cash on hand.
Offer expected to commence ~Aug 24, 2026 and expire ~Sep 29, 2026; subject to Canadian/US exemptive relief.
CEO cites March 2026 Moderna settlement and July 2026 initial payment as funding source for the buyback.
J.P. Morgan Securities LLC is dealer-manager; Georgeson LLC and TSX Trust are info agent and depositary.
Company will continue to enforce LNP patent rights against Pfizer and BioNTech alongside licensee Genevant.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.